Home LiteratureArticle Details
PMID: 22822074 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Biochemical analysis of hypermutation by the deoxycytidine deaminase APOBEC3A.

The Journal of biological chemistry ·Vol. 287 ·No. 36 ·2012-08-31 ·Pages 30812-22

Love RP, Xu H, Chelico L

Abstract

APOBEC3A belongs to a family of single-stranded DNA (ssDNA) DNA cytosine deaminases that are known for restriction of HIV through deamination-induced mutational inactivation, e.g. APOBEC3G, or initiation of somatic hypermutation and class switch recombination (activation-induced cytidine deaminase). APOBEC3A, which is localized to both the cytoplasm and nucleus, not only restricts HIV but can also initiate catabolism of cellular DNA. Despite being ascribed these roles, there is a paucity of data available on the biochemical mechanism by which APOBEC3A deaminates ssDNA. Here we assessed APOBEC3A deamination activity on ssDNA and in dynamic systems modeling HIV replication (cytoplasmic event) and DNA transcription (nuclear event). We find that APOBEC3A, unlike the highly processive APOBEC3G, exhibits low or no processivity when deaminating synthetic ssDNA substrates with two cytosines located 5-63 nucleotides apart, likely because of an apparent K(d) in the micromolar range (9.1 μm). APOBEC3A was able to deaminate nascently synthesized (-)DNA in an in vitro model HIV replication assay but induced fewer mutations overall in comparison to APOBEC3G. However, the data indicate that the target deamination motif (5'-TC for APOBEC3A and 5'-CC for APOBEC3G) and not the number of mutations best predicted the ability to mutationally inactivate HIV. We further assessed APOBEC3A for the ability to deaminate dsDNA undergoing transcription, which could allow for collateral deaminations to occur in genomic DNA similar to the action of activation-induced cytidine deaminase. That APOBEC3A was able to deaminate dsDNA undergoing transcription suggests a genomic cost of a deamination-based retroviral restriction system.

MeSH Terms
APOBEC-3G Deaminase Cell Nucleus/enzymology,genetics Cytidine Deaminase/genetics,metabolism Cytoplasm/enzymology,genetics DNA, Viral/genetics,metabolism HIV-1/physiology Humans Mutation Proteins/genetics,metabolism Transcription, Genetic/genetics Virus Replication/physiology
Chemicals
DNA, Viral Proteins APOBEC-3G Deaminase APOBEC3A protein, human APOBEC3G protein, human Cytidine Deaminase
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Love Robin P
Department of Microbiology and Immunology, University of Saskatchewan, Saskatoon, Saskatchewan S7N 5E5, Canada.
Xu Huixin
Chelico Linda
References (69)
69 references, click to expand
  1. Comparison of the differential context-dependence of DNA deamination by APOBEC enzymes: correlation with mutation spectra in vivo.
    J Mol Biol. 2004 Mar 26;337(3):585-96 PMID: 15019779
  2. Activation-induced cytidine deaminase deaminates deoxycytidine on single-stranded DNA but requires the action of RNase.
    Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):4102-7 PMID: 12651944
  3. Single-stranded DNA scanning and deamination by APOBEC3G cytidine deaminase at single molecule resolution.
    J Biol Chem. 2012 May 4;287(19):15826-35 PMID: 22362763
  4. The biochemistry of somatic hypermutation.
    Annu Rev Immunol. 2008;26:481-511 PMID: 18304001
  5. Complete mutagenesis of the HIV-1 protease.
    Nature. 1989 Aug 3;340(6232):397-400 PMID: 2666861
  6. APOBEC3G DNA deaminase acts processively 3' --> 5' on single-stranded DNA.
    Nat Struct Mol Biol. 2006 May;13(5):392-9 PMID: 16622407
  7. The APOBEC3 cytidine deaminases: an innate defensive network opposing exogenous retroviruses and endogenous retroelements.
    Annu Rev Immunol. 2008;26:317-53 PMID: 18304004
  8. APOBEC3G genetic variants and their influence on the progression to AIDS.
    J Virol. 2004 Oct;78(20):11070-6 PMID: 15452227
  9. Processive AID-catalysed cytosine deamination on single-stranded DNA simulates somatic hypermutation.
    Nature. 2003 Jul 3;424(6944):103-7 PMID: 12819663
  10. APOBEC3G mRNA expression in exposed seronegative and early stage HIV infected individuals decreases with removal of exposure and with disease progression.
    Retrovirology. 2009 Mar 02;6:23 PMID: 19254362
  11. Target cell-mediated editing of HIV-1 cDNA by APOBEC3 proteins in human macrophages.
    J Virol. 2011 Dec;85(24):13448-52 PMID: 21957290
  12. APOBEC3 proteins inhibit human LINE-1 retrotransposition.
    J Biol Chem. 2006 Aug 4;281(31):22161-22172 PMID: 16735504
  13. APOBEC3A is a specific inhibitor of the early phases of HIV-1 infection in myeloid cells.
    PLoS Pathog. 2011 Sep;7(9):e1002221 PMID: 21966267
  14. Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome.
    Nat Struct Mol Biol. 2004 May;11(5):435-42 PMID: 15098018
  15. The heterosexual human immunodeficiency virus type 1 epidemic in Thailand is caused by an intersubtype (A/E) recombinant of African origin.
    J Virol. 1996 Oct;70(10):7013-29 PMID: 8794346
  16. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein.
    Nature. 2002 Aug 8;418(6898):646-50 PMID: 12167863
  17. Somatic hypermutation of human mitochondrial and nuclear DNA by APOBEC3 cytidine deaminases, a pathway for DNA catabolism.
    Proc Natl Acad Sci U S A. 2011 Mar 22;108(12):4858-63 PMID: 21368204
  18. HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability.
    Mol Cell. 2003 Sep;12(3):591-601 PMID: 14527406
  19. Mutations in activation-induced cytidine deaminase in patients with hyper IgM syndrome.
    Clin Immunol. 2000 Dec;97(3):203-10 PMID: 11112359
  20. Human immunodeficiency virus type 1 Vif functionally interacts with diverse APOBEC3 cytidine deaminases and moves with them between cytoplasmic sites of mRNA metabolism.
    J Virol. 2008 Jan;82(2):987-98 PMID: 17977970
  21. DNA deamination mediates innate immunity to retroviral infection.
    Cell. 2003 Jun 13;113(6):803-9 PMID: 12809610
  22. Hypermutation by intersegmental transfer of APOBEC3G cytidine deaminase.
    Nat Struct Mol Biol. 2008 Oct;15(10):1059-66 PMID: 18820687
  23. The Vif protein of HIV triggers degradation of the human antiretroviral DNA deaminase APOBEC3G.
    Curr Biol. 2003 Nov 11;13(22):2009-13 PMID: 14614829
  24. Structural model for deoxycytidine deamination mechanisms of the HIV-1 inactivation enzyme APOBEC3G.
    J Biol Chem. 2010 May 21;285(21):16195-205 PMID: 20212048
  25. 'Binding, bending and bonding': polypurine tract-primed initiation of plus-strand DNA synthesis in human immunodeficiency virus.
    Int J Biochem Cell Biol. 2004 Sep;36(9):1752-66 PMID: 15183342
  26. Cytidine deamination induced HIV-1 drug resistance.
    Proc Natl Acad Sci U S A. 2008 Apr 8;105(14):5501-6 PMID: 18391217
  27. The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif.
    Nat Med. 2003 Nov;9(11):1404-7 PMID: 14528300
  28. Cellular inhibitors of long interspersed element 1 and Alu retrotransposition.
    Proc Natl Acad Sci U S A. 2006 Jun 6;103(23):8780-5 PMID: 16728505
  29. The HIV-1 central polypurine tract functions as a second line of defense against APOBEC3G/F.
    J Virol. 2010 Nov;84(22):11981-93 PMID: 20844042
  30. Retroviral restriction by APOBEC proteins.
    Nat Rev Immunol. 2004 Nov;4(11):868-77 PMID: 15516966
  31. APOBEC3A can activate the DNA damage response and cause cell-cycle arrest.
    EMBO Rep. 2011 May;12(5):444-50 PMID: 21460793
  32. Rapid purification of homodimer and heterodimer HIV-1 reverse transcriptase by metal chelate affinity chromatography.
    Eur J Biochem. 1990 Jan 26;187(2):307-14 PMID: 1688798
  33. A model for oligomeric regulation of APOBEC3G cytosine deaminase-dependent restriction of HIV.
    J Biol Chem. 2008 May 16;283(20):13780-91 PMID: 18362149
  34. The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA.
    Nature. 2003 Jul 3;424(6944):94-8 PMID: 12808465
  35. AID upmutants isolated using a high-throughput screen highlight the immunity/cancer balance limiting DNA deaminase activity.
    Nat Struct Mol Biol. 2009 Jul;16(7):769-76 PMID: 19543289
  36. Determination of molecular masses of proteins in solution: Implementation of an HPLC size exclusion chromatography and laser light scattering service in a core laboratory.
    J Biomol Tech. 1999 Jun;10(2):51-63 PMID: 19499008
  37. AID is required for the chromosomal breaks in c-myc that lead to c-myc/IgH translocations.
    Cell. 2008 Dec 12;135(6):1028-38 PMID: 19070574
  38. Defining APOBEC3 expression patterns in human tissues and hematopoietic cell subsets.
    J Virol. 2009 Sep;83(18):9474-85 PMID: 19587057
  39. APOBEC3G is a single-stranded DNA cytidine deaminase and functions independently of HIV reverse transcriptase.
    Nucleic Acids Res. 2004 Apr 30;32(8):2421-9 PMID: 15121899
  40. Origin of chromosomal translocations in lymphoid cancer.
    Cell. 2010 Apr 2;141(1):27-38 PMID: 20371343
  41. Electron tomography analysis of envelope glycoprotein trimers on HIV and simian immunodeficiency virus virions.
    Proc Natl Acad Sci U S A. 2003 Dec 23;100(26):15812-7 PMID: 14668432
  42. The retroviral hypermutation specificity of APOBEC3F and APOBEC3G is governed by the C-terminal DNA cytosine deaminase domain.
    J Biol Chem. 2005 Mar 25;280(12):10920-4 PMID: 15647250
  43. Gel fidelity assay measuring nucleotide misinsertion, exonucleolytic proofreading, and lesion bypass efficiencies.
    Methods Enzymol. 1995;262:232-56 PMID: 8594351
  44. Diffusion-driven mechanisms of protein translocation on nucleic acids. 1. Models and theory.
    Biochemistry. 1981 Nov 24;20(24):6929-48 PMID: 7317363
  45. APOBEC3G-depleted resting CD4+ T cells remain refractory to HIV1 infection.
    PLoS One. 2009 Aug 10;4(8):e6571 PMID: 19668336
  46. APOBEC3 proteins mediate the clearance of foreign DNA from human cells.
    Nat Struct Mol Biol. 2010 Feb;17(2):222-9 PMID: 20062055
  47. The stoichiometry of Gag protein in HIV-1.
    Nat Struct Mol Biol. 2004 Jul;11(7):672-5 PMID: 15208690
  48. Hyper-IgM syndromes.
    Curr Opin Rheumatol. 2006 Jul;18(4):369-76 PMID: 16763457
  49. Complementary function of the two catalytic domains of APOBEC3G.
    Virology. 2005 Mar 15;333(2):374-86 PMID: 15721369
  50. Intensity of deoxycytidine deamination of HIV-1 proviral DNA by the retroviral restriction factor APOBEC3G is mediated by the noncatalytic domain.
    J Biol Chem. 2011 Apr 1;286(13):11415-26 PMID: 21300806
  51. Stoichiometry of the antiviral protein APOBEC3G in HIV-1 virions.
    Virology. 2007 Apr 10;360(2):247-56 PMID: 17126871
  52. APOBEC3A and APOBEC3B are potent inhibitors of LTR-retrotransposon function in human cells.
    Nucleic Acids Res. 2006 Jan 10;34(1):89-95 PMID: 16407327
  53. APOBEC3A is a potent inhibitor of adeno-associated virus and retrotransposons.
    Curr Biol. 2006 Mar 7;16(5):480-5 PMID: 16527742
  54. Effects of point mutations in the cytidine deaminase domains of APOBEC3B on replication and hypermutation of hepatitis B virus in vitro.
    J Gen Virol. 2007 Dec;88(Pt 12):3270-3274 PMID: 18024895
  55. Regulation of hypermutation by activation-induced cytidine deaminase phosphorylation.
    Proc Natl Acad Sci U S A. 2006 Jun 6;103(23):8798-803 PMID: 16723391
  56. The intrinsic antiretroviral factor APOBEC3B contains two enzymatically active cytidine deaminase domains.
    Virology. 2007 Aug 1;364(2):486-93 PMID: 17434555
  57. Reassessing the role of APOBEC3G in human immunodeficiency virus type 1 infection of quiescent CD4+ T-cells.
    PLoS Pathog. 2009 Mar;5(3):e1000342 PMID: 19300495
  58. How do site-specific DNA-binding proteins find their targets?
    Nucleic Acids Res. 2004 Jun 03;32(10):3040-52 PMID: 15178741
  59. Characterization of T7 RNA polymerase transcription complexes assembled on nucleic acid scaffolds.
    J Biol Chem. 2002 Dec 6;277(49):47035-43 PMID: 12351656
  60. Two levels of protection for the B cell genome during somatic hypermutation.
    Nature. 2008 Feb 14;451(7180):841-5 PMID: 18273020
  61. Twin gradients in APOBEC3 edited HIV-1 DNA reflect the dynamics of lentiviral replication.
    Nucleic Acids Res. 2006;34(17):4677-84 PMID: 16963778
  62. Stably expressed APOBEC3F has negligible antiviral activity.
    J Virol. 2010 Nov;84(21):11067-75 PMID: 20702622
  63. An anthropoid-specific locus of orphan C to U RNA-editing enzymes on chromosome 22.
    Genomics. 2002 Mar;79(3):285-96 PMID: 11863358
  64. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts.
    Nature. 2003 Jul 3;424(6944):99-103 PMID: 12808466
  65. Atomic force microscopy studies provide direct evidence for dimerization of the HIV restriction factor APOBEC3G.
    J Biol Chem. 2011 Feb 4;286(5):3387-95 PMID: 21123176
  66. Stochastic properties of processive cytidine DNA deaminases AID and APOBEC3G.
    Philos Trans R Soc Lond B Biol Sci. 2009 Mar 12;364(1517):583-93 PMID: 19022738
  67. HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation.
    Nat Med. 2003 Nov;9(11):1398-403 PMID: 14528301
  68. AID produces DNA double-strand breaks in non-Ig genes and mature B cell lymphomas with reciprocal chromosome translocations.
    Mol Cell. 2009 Nov 25;36(4):631-41 PMID: 19941823
  69. Quantitative profiling of the full APOBEC3 mRNA repertoire in lymphocytes and tissues: implications for HIV-1 restriction.
    Nucleic Acids Res. 2010 Jul;38(13):4274-84 PMID: 20308164
Article Info
Journal
The Journal of biological chemistry
Abbr.
J Biol Chem
ISSN
1083-351X
Published
2012-08-31
Epub
2012-00-20
Pages
30812-22
Language
English
Region
United States
NLM ID
2985121R
PMCID
PMC3436324
Subset
IM
Grants
NCRR NIH HHS · S10 RR023748 · United States
NCRR NIH HHS · ISI0RR023748-01 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com